Product Description
Ref-SKU:
017V-05966 Infectious cell culture supernatant of human SARS-CoV-2 containing hCoV-19/France/GES-IPP04895/2024, lineage KP.2
Product Risk Group:
ICTV Taxonomy:
Genotype:
Storage conditions:
Viral Storage Medium -80C
Sequencing:
Complete genome
Infectivity:
Infectivity tested and quantified
Mycoplasmic content:
Mycoplasma free
Special feature:
GMO:
No
Biosafety restrictions:
BSL3 biosafety procedures
Virus host type:
Infectivity Test:
Plaque assay
Production cell line:
Virus Cultivability:
Passage:
C2
Shipping conditions:
IATA Classification:
Comments (1)
VisMederi, a medium research enterprise based in Italy, would like to acquire the present KP.2 SARS-COV-2 variant with the aim to set-up, standardize and validate a new high through-put microneutralization assay for the determination and semi-quantitation of neutralizing antibodies in human and animal samples. The scientific aim of the study would be to investigate the immunological mechanisms of protection and, the viral escape from the immunity elicited by means of previous exposure and/or vaccination. The study is a follow up of previous projects aimed to assess the persistence of neutralizing antibodies towards SARS-COV-2 Omicron sublineage after the third vaccine dose. (doi: 10.1016/j.actatropica.2023.107042).